Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
at the current SP i wouldn't call it "chasing"?!
nope, i could not enter the ticker into the IB TraderWorkStation, it said this symbol is not available or allowed for my account...
funny thing is i can buy MCII now if i wanted to?!
IB = http://www.interactivebrokers.com/ ;)
and still is... also i'm riding it with free shares ^^
haven't received my MAQC roundup yet, but bought some :)
my broker (IB) has yet to respond to my email i send them a few days ago...
EXEG - AMEX news... will begin trading on monday as OPK :)
http://www.investorshub.com/boards/read_msg.asp?message_id=20292897
AMUG 0.70 x 0.74 ^^
eXegenics Changes Name to Opko Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Friday June 8, 8:00 am ET
MIAMI, June 8 /PRNewswire-FirstCall/ -- eXegenics, Inc. (OTC Bulletin Board: EXEG - News) today announced that it has completed its name change to Opko Health Inc. The company also announced its common stock has been approved for listing on the American Stock Exchange (AMEX). Opko's stock is expected to begin trading on the AMEX exchange under the ticker symbol OPK on Monday, June 11, 2007.
"Now that we are officially Opko Health, it is fitting that our shares have been approved for listing on the American Stock Exchange," said Dr. Philip Frost, chairman and CEO of Opko Health, Inc. "The improved visibility and liquidity available to us as an AMEX-listed company should contribute to our efforts to advance our ophthalmic businesses and build shareholder value."
This approval is contingent upon Opko being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if the company is not in compliance with such standards.
About Opko Health
Miami-based Opko Health was recently reconstituted as a specialty healthcare company through a 3-way merger of eXegenics, Inc. with private companies Acuity Pharmaceuticals Inc., and Froptix, Inc. Its product portfolio includes the pioneering gene silencing agent bevasiranib, which has successfully completed Phase ll clinical trials for wet age-related macular degeneration and diabetic macular edema; a novel clinical stage product for conjunctivitis; and a pipeline of preclinical candidates that include novel agents to treat dry age-related macular degeneration and other ophthalmic diseases. The company also intends to market selected diagnostic products that are complementary to its therapeutic programs.
Source: Opko Health
Summus Works, Inc. Announces November 6, 2006 Record Date for Atlantis Holding Corp Dividend to Shareholders; Pay Date Is November 20, 2006
Administrator User <infoSPAMFILTER@highanglemedia.com>
Wednesday November 29 2006
DENVER, CO, Nov 02, 2006
Summus Works, Inc. (PINKSHEETS: SMMW) announced that in accordance with requirements necessary to the Company's dividend distribution of the its one million shares of restricted Atlantis Holding Corp. common stock, the record date for shareholders receiving the dividend shall be November 6, 2006. Shareholders of record as of November 6 will receive, par rata, the dividend shares of Atlantis Holding Corp. (PINKSHEETS: AHDG), to be paid on November 20, 2006, without any shareholder action.
yup, SQUM is a real fully reporting company and nowadays ppl are only interested in SCAMS like CKYS, SLJB, PAIM, PNMS and so on...
:)
LOL what did you expect?
this is a JMCP shell... big mouth, and nothing to back it up ;)
their PR's sound like pure BS and hype! and that's what they are about hype... IMHO!
when i read those PR's by JMCP and ONYI i know that those guys are full of it...
did you ever really read those PR's?
Landmark Study Shows Diachrome(R) Significantly Improves Blood Sugar Control in People with Type 2 Diabetes
Monday June 4, 9:00 am ET
Greatest Improvement Seen in Patients with Poorest Degree of Control
PURCHASE, N.Y.--(BUSINESS WIRE)--Nutrition 21, Inc. (NASDAQ: NXXI - News) today announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome®, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs). Patients in the treatment group showed significant improvements in glycemic control (A1C) compared with placebo (an absolute decrease of 0.54%). The greatest improvement was seen in those patients with the poorest glycemic control (baseline A1C levels equal to or greater than 10%). These patients saw an additional absolute A1C decrease of 1.76% despite the fact that they were taking one or more OAD medications.
The American Diabetes Association's (ADA) recommended goal for type 2 diabetes patients is an A1C level below 7.0%. Lowering A1C by just 1%, especially in patients with poor blood sugar control, can delay or prevent serious complications, reduce diabetes-related deaths(1) and reduce healthcare costs.
"Uncontrolled, obese and overweight type 2 diabetes patients present an ongoing clinical challenge to health professionals. Prescribing another anti-diabetic medication can increase the risk of unwanted side effects, including weight gain or hypoglycemic events, and could place an added financial burden on the patient," said Cesar Albarracin, MD, lead investigator and a leader in the field of nutritional management of type 2 diabetes. "This study shows that adding Diachrome to anti-diabetic medications can help patients reach their blood sugar goal simply, effectively and safely."
About the study
The randomized, double-blind, placebo-controlled, 90-day study, published online in Diabetes/Metabolism Research and Reviews (http://www3.interscience.wiley.com/cgi-bin/abstract/114263457/ ABSTRACT), measured reductions in A1C, fasting glucose and lipids in 447 obese and/or overweight adults with type 2 diabetes on oral anti-diabetic medications. Safety and tolerability were also assessed. Results showed a significant reduction in A1C levels for the treatment group (-0.54%) compared with the placebo group (-0.34%). The highest risk patients (baseline A1C equal to or greater than 10%) showed an even greater improvement in A1C when compared to placebo (-1.76% vs. -0.68%).(2)(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Fasting glucose levels, a measure of blood sugar after one has not eaten for at least eight hours, also showed significant reductions in the entire treatment group (-9.8 mg/dL) compared with placebo (0.7 mg/dL). Once again, the decrease was greater for the highest risk patients when compared with placebo (-35.8 mg/dL vs. 16.2 mg/dL). Diachrome was well tolerated and adverse effects and the clinical safety profile for the active group was not significantly different from placebo.
Those individuals receiving chromium picolinate plus biotin, in the form of Diachrome, also experienced a significant decrease in triglycerides to HDL ratio compared to the placebo group (p=0.05 vs. placebo). A study published in the March 2007 issue of the American Journal of the Medical Sciences also showed that chromium picolinate plus biotin added to OADs helped improve lipid control over a 30-day period by improving triglycerides-to-HDL ratio and LDL-to-HDL ratio.(3)
"The publication of this landmark study, which followed a phase III pharmaceutical-equivalent design, reinforces our belief that Diachrome will become a standard tool for public and private healthcare professionals charged with managing the growing epidemic of type 2 diabetes," said Paul Intlekofer, CEO of Nutrition 21. "Diachrome's drug-like effects in safely and effectively improving both blood glucose and cholesterol levels in the most severe diabetes patients is significant, as this population is generally the hardest to control, the most costly to care for and the most likely to develop complications. With these clinical research outcomes, Diachrome's drug retail presence will expand beyond CVS and Walgreens."
The form of chromium in Diachrome, Chromax® chromium picolinate, that was used in these studies has been recognized as safe by many of the world's leading government and academic research institutions, including the U.S. Food & Drug Administration (FDA), the Institute of Medicine and the UK's Food Standards Agency. In addition, both Chromax chromium picolinate and biotin have been deemed safe by the FDA and are also Generally Recognized as Safe (GRAS) for use in foods and supplements.
About Diachrome
Diachrome is a non-prescription nutrient-based therapy formulated to help support blood glucose management in people with diabetes. It is composed of two safe and beneficial nutrients: chromium (as Chromax chromium picolinate) and biotin (a B-vitamin). Scientific evidence indicates that Diachrome's unique ingredient combination works synergistically to produce positive effects on insulin function, blood glucose, lipid metabolism and cardiovascular health. The nutritional therapy can be found in drug retail stores nationwide.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium picolinate-based, selenium and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds over 30 patents for nutrition products and uses. The company markets Chromax® chromium picolinate, which is the most-studied form of the essential mineral chromium. Chromax, a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism, cardiovascular disease, control cravings and fight weight gain, is now available through food, drug and mass retailers nationwide. Another chromium picolinate-based supplement developed and marketed by Nutrition 21 is Diachrome®, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. It is sold in select drug retailers nationwide. Nutrition 21 also markets Selenomax®, a high selenium yeast supplement that stimulates and protects the immune system by supporting antibody production and preventing free-radical damage. Selenomax is available at CVS/pharmacy in all its 6,200 retail stores nationwide, including PharmaCare Specialty Pharmacy locations, and on www.cvs.com. The Company is the exclusive importer of Icelandic fish oils, including omega-3 fatty acids, which are manufactured to pharmaceutical standards and sold under the Iceland Health® brand. More information is available at http://www.nutrition21.com/.
(1) Stratton IM, Adler AI, Andrew H, Neil W, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (on behalf of the U.K. Prospective Diabetes Study Group): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000.
(2) Albarracin C.A. et al. Diabetes/Metabolism Research and Reviews. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Available at: http://www3.interscience.wiley.com/cgi-bin/abstract/114263457/ABSTRACT
(3) Geohas J et al. American Journal of the Medical Sciences. 333(3):145-153, March 2007.
Contact:
Nutrition 21, Inc.
Maryrose Lombardo, 914-701-4525
Chad Hyett, 212-453-2493
Source: Nutrition 21, Inc.
you really think JMCP/ONYI is not a SCAM? c'mon
maybe weeks...
also i got NWMO the next day with IB i'm still waiting for my DSKT/DSKA roundup shares since 2 month or so and also i'm waiting for my MKAQ/MACQ roundup...
yep
i hope it works out for those who got them :)
congrats, i couldn't buy them through IB :(
nice one, couldn't buy them through IB :(
a CEO also needs a break from time to time and a good laugh about some posts is healthy imho ;)
Opko Health, Inc. to Acquire Diagnostic Imaging Firm
Friday June 1, 8:00 am ET
--Hires Industry Veteran as Executive Vice President of Instrumentation--
MIAMI, June 1 /PRNewswire-FirstCall/ -- eXegenics, Inc., (OTC Bulletin Board: EXEG - News), doing business as Opko Health, today announced that it has entered into an agreement to acquire Ophthalmic Technologies, Inc. (OTI), a private Canadian company providing innovative patient imaging systems to eye care professionals worldwide. Additionally, Opko announced it has hired Steven Verdooner as Executive Vice President of Instrumentation, a newly created position.
"It is fitting that among our first actions as Opko Health is the acquisition of a respected ocular diagnostics firm and the hiring of an experienced senior manager from the diagnostics industry," said Dr. Philip Frost, Chairman and CEO of Opko Health. "There is the potential for powerful synergies between our therapeutics pipeline and the diagnostic systems and devices used by eye care professionals, and we believe OTI will be a good strategic foundation for that business. We are delighted that Steve Verdooner is joining Opko and believe his extensive experience in ophthalmic diagnostic instrumentation will be very valuable as we build our presence in this sector."
Toronto-based OTI provides technologically advanced, easy-to-use diagnostic and imaging equipment to the ophthalmology community. It markets a full line of advanced ophthalmic ultrasound and imaging products used by eye care professionals for both routine and specialized care. The company's SLO/OCT system is a breakthrough product offering unique advantages over current technology and providing a flexible platform that can process a wide variety of diagnostic tests. OTI has offices in Canada, the U.S. and the U.K. and a growing distributor network that currently covers more than 40 countries.
Rishard Weitz, President and CEO of OTI said, "As a team that has successfully commercialized innovative ophthalmic diagnostic imaging technologies, we are pleased to join forces with Opko, where we see the combination of strategic vision and successful companies with advanced technologies having the potential to create a new leader in the growing ophthalmology field."
According to the terms of the agreement with OTI, Opko has purchased one- third of the outstanding common shares of the company and has received an exclusive option to purchase the remaining shares over a period of approximately six months. Further details of the agreement are included in the company's 8-K filing with the Securities and Exchange Commission.
Steven Verdooner joins Opko from Ophthalmic Imaging Systems (OIS), a market leader in the field of ophthalmic digital imaging and informatics. Mr. Verdooner co-founded OIS in 1984 and played a major role in its growth and market success, including the development and marketing of revolutionary new ophthalmic imaging systems. In his more than 20 years at OIS, Mr. Verdooner had responsibility for a wide variety of functional areas, serving as Executive Vice President, President, Chief Executive Officer and Chairman. He received a B.S. degree from the University of California, Davis.
Source: eXegenics, Inc.
got it also today via snail mail, and i live in Germany!
nice board btw :)
New Website Coming Soon!
http://www.opko.com/
maybe because i'm german but i don't get your point?!
does the first Mc Donald's look like those today?
do you know how a uWink restaurant will look like in a few years??
do you always buy a new PC if your CPU is 100 MHZ below the new ones??
UWNK has developed their own games and terminals where customers can play and interact in a social environment while they are eating, drinking, and having fun. The games are very casual and simple to play so that women who normally don't play games can participate.
yup, time to avarage up for me now :)
$2,400.00 is alot of money for some... better than $0.00 ;)
late print, MM covers the dilution that's going on imho!
no, there is no volume... yahoo data is incorrect
http://aktien.wallstreet-online.de/6531/handelsplaetze.html
i tradet this stock last week... made a small profit but the dilution here kills every pop imho!
of course pawson sucks... all conartists do ;)
as if there would be anything left to give to the shareholders?!
we mean 0.08 sorry :)
with IB i also got the shares the next day and sold @ 80 bought back at 50 and sold again @ 70 and just bought again :)
that data from yahoo is wrong...
http://aktien.wallstreet-online.de/2084.html?&inst_id=2084&market_id=8&spid=ws&m=1.1...
only 4M were tradet in Stuttgart today...
yahoo must have an error... as so often lately
you are correct, no 11M volume in frankfurt there is NO volume...
http://finance.yahoo.com/q?s=CB3A.F
of course not... to many shares to sell by him ;)
no, i made my money back elsewhere...
GTE/L/M was a valuable lesson to learn for me :)
as fact? i just wanted to know why they don't show the world some numbers and contracts that would take care of the shorts...
just blaming them is not a good business model longer term i think!
what about VozBrazil or iLigue?
the best we can do is continue to build the business and generate positive developments that add value to GlobeTel?
why don't they do that?
who else could do it instead of mr. reed? rob??
there are not that many employees left @ GTEM
IMHO
nice article, great find! :)